Highlighting Key Follicular Lymphoma Data Following ASH 2024

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss key updates in the follicular lymphoma field following the 2024 ASH Annual Meeting

EP. 1: Dissecting the Current Treatment Landscape for R/R Follicular Lymphoma

December 20th 2024

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.

EP. 2: The Phase 3 inMIND Trial: Tafasitamab Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for tafasitamab in relapsed/refractory follicular lymphoma.

EP. 3: Clinical Experience Using Tafasitamab Plus Lenalidomide in DLBCL

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss their clinical practice experience using tafasitamab in relapsed/refractory DLBCL.

EP. 4: CD19 Expression Loss and Tafasitamab in R/R DLBCL

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss CD19 expression and the use of tafasitamab in relapsed/refractory DLBCL.

EP. 5: 2-Year Follow-Up Data for Liso-Cel in R/R Follicular Lymphoma

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss 2-year follow-up data for liso-cel in relapsed/refractory follicular lymphoma.

EP. 6: Data for Mosunetuzumab in Newly Diagnosed Follicular Lymphoma

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for mosunetuzumab in newly diagnosed follicular lymphoma.

EP. 7: Other Key Follicular Lymphoma Data From ASH 2024

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss follicular lymphoma data from ASH 2024.